Drug Shortage Report for LEVOTHYROXINE SODIUM FOR INJECTION
| Report ID | 261393 |
| Drug Identification Number | 02245948 |
| Brand name | LEVOTHYROXINE SODIUM FOR INJECTION |
| Common or Proper name | LEVOTHYROXINE SODIUM FOR INJECTION |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | LEVOTHYROXINE SODIUM |
| Strength(s) | 500MCG |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 500 mcg |
| ATC code | H03AA |
| ATC description | THYROID PREPARATIONS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2025-07-15 |
| Actual start date | |
| Estimated end date | 2025-09-02 |
| Actual end date | 2025-08-27 |
| Shortage status | Resolved |
| Updated date | 2025-08-28 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Levothyroxine Sodium for Injection 500 mcg, Vial effective July 15, 2025, until September 2, 2025. During this gap, our Levothyroxine Sodium Injection 100 mcg/mL, 5 mL Vial will be made available as a substitute. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v8 | 2025-08-28 | English | Compare |
| v7 | 2025-08-27 | French | Compare |
| v6 | 2025-08-27 | English | Compare |
| v5 | 2025-08-13 | French | Compare |
| v4 | 2025-08-13 | English | Compare |
| v3 | 2025-07-16 | English | Compare |
| v2 | 2025-06-30 | French | Compare |
| v1 | 2025-06-30 | English | Compare |
Showing 1 to 8 of 8